Mason Capital Acquires Forward Pharma A/S via Tender Offer

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Danforth Advisors Acquires PharmaDirections

August 25, 2025

Healthcare Services

Danforth Advisors, a PE-backed life sciences advisory platform, has acquired PharmaDirections, a virtual drug development partner. The acquisition adds more than 150 specialists and expands Danforth's integrated capabilities across discovery, non-clinical and clinical development, CMC, regulatory strategy, and program and alliance management.

Nordic Capital and Permira to Acquire Bavarian Nordic for About $3 Billion

July 31, 2025

Biotechnology

Bavarian Nordic A/S has accepted a takeover offer valued at DKK 19 billion (about $2.99 billion) from a consortium of Nordic Capital and Permira. Shareholders will receive an all-cash offer of 233 Danish kroner per share, and the deal is expected to close in the fourth quarter of 2025 subject to regulatory approvals and acceptance conditions.

CSL Limited Acquires Vifor Pharma Ltd in All-Cash Tender Offer

December 14, 2021

Pharmaceuticals

CSL Limited entered into a definitive agreement to acquire Vifor Pharma Ltd via an all-cash public tender offer at US$179.25 per share (aggregate equity value about US$11.7 billion). The transaction was funded through a mix of placement, new debt, and existing cash/facilities and was expected to complete around mid-2022, subject to regulatory approvals.

Jazz Pharmaceuticals Acquires GW Pharmaceuticals for $7.2 billion

February 3, 2021

Pharmaceuticals

Jazz Pharmaceuticals plc has entered into a definitive agreement to acquire GW Pharmaceuticals plc for $220 per ADS (comprised of $200 cash and $20 in Jazz ordinary shares), implying total consideration of approximately $7.2 billion ($6.7 billion net of GW cash). The boards of both companies approved the transaction, which is expected to close in Q2 2021 subject to GW shareholder approval, court sanction and customary regulatory clearances; the combined company will strengthen Jazz's neuroscience portfolio and global commercial footprint.

Thomas H. Lee Partners and Frazier Healthcare Partners Acquire Adare Pharmaceuticals

September 22, 2020

Pharmaceuticals

Thomas H. Lee Partners and Frazier Healthcare Partners have acquired Adare Pharmaceuticals (to be rebranded Adare Pharma Solutions) from TPG Capital. The deal includes Adare’s CDMO, pharmaceutical technology and microbiome businesses while TPG retained rights to an EoE product spun into a separate entity; terms were not disclosed.